Table 1.
Patient baseline characteristics
| Lenvatinib Eastern population % |
Lenvatinib Italian population % |
Sorafenib % |
P value between the two cohorts of lenvatinib | P value between lenvatinib Eastern population and sorafenib | |
|---|---|---|---|---|---|
| Age, years | |||||
| <70 | 34.4 | 51.2 | 59.8 | 0.0008 | <0.00001 |
| >70 | 65.6 | 48.8 | 40.3 | ||
| Sex | |||||
| Male | 78.0 | 75.6 | 88.1 | 0.62 | 0.0004 |
| Female | 22.0 | 24.4 | 11.9 | ||
| BCLC stage | |||||
| B | 58.2 | 22.0 | 25.1 | <0.000001 | <0.000001 |
| C | 41.8 | 78.0 | 74.9 | ||
| Etiology | |||||
| HCV | 43.3 | 48.0 | 51.4 | ||
| HBV | 14.6 | 15.0 | 20.6 | 0.07 | 0.0004 |
| Others | 42.1 | 37.0 | 28.0 | ||
| Performance status | |||||
| 0 | 86.6 | 86.6 | 61.4 | 1.00 | <0.000001 |
| 1 | 13.4 | 13.4 | 38.6 | ||
| Portal vein thrombosis | |||||
| No | 85.6 | 72.4 | 61.1 | 0.001 | <0.000001 |
| Yes | 14.4 | 27.6 | 38.9 | ||
| Child–Pugh score | |||||
| A | 88.6 | 94.5 | 92.6 | ||
| B | 11.4 | 5.5 | 7.4 | 0.06 | 0.07 |
| AFP | |||||
| <400 | 74.7 | 57.6 | 68.5 | 0.0003 | 0.06 |
| >400 | 25.3 | 42.4 | 31.5 | ||
| TACE | |||||
| Yes | 65.8 | 41.7 | 49.8 | 0.00002 | 0.00001 |
| No | 34.2 | 58.3 | 50.2 | ||
| ALBI | |||||
| 1 | 89.1 | 91.9 | 93.6 | 0.40 | 0.04 |
| 2 | 10.9 | 8.1 | 6.4 | ||
| PNI | |||||
| <43.3 | 49.7 | 33.1 | 86.5 | 0.001 | <0.000001 |
| >43.3 | 50.3 | 66.9 | 13.5 |
The positive results were in bold.
AFP, α-fetoprotein; ALBI, albumin-bilirubin score; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; PNI, prognostic nutritional index; TACE, trans-arterial chemoembolization.